‘Anti-VEGFs Have Reached Their Limit:’ EyeBio Targets New Pathway For Eye Therapies
Potential First-In-Class Wnt Agonist
Led by the duo who brought the first anti-VEGF drug to market, EyeBio aims to develop the next breakthrough eye therapy via a novel tri-specific antibody.
You may also be interested in...
Roche said it remains deeply committed to the therapeutic area and highlighted a broad clinical pipeline at a virtual investor event.
Roche’s next-generation eye drug Vabysmo has enjoyed a strong launch, but new head-to-head trials in a potential new indication, retinal vein occlusion, appear to offers up few advantages over market leader Eylea.
The withdrawal of the targeted anticancer comes as no surprise after its Phase III missed in July, but it sets back Takeda’s expansion plans in the competitive therapy area.